

# PHARMACOLOGY

**ADR**

MONITORING  
&  
REPORTING

**Adverse Drug  
Reaction**

Merlin Dinesh  
M.Sc. CREM  
CARE

## ADVERSE DRUG REACTIONS (ADR)

An adverse drug reaction is a “response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function.”

**CLASSIFICATION-** Depending on severity of reaction

<b>Minor</b>	<b>Moderate</b>	<b>Severe</b>	<b>Lethal</b>
No treatment/ antidote/ prolongation of treatment needed	Requires treatment/ change in treatment/ Prolongation by at least 1 day	Life threatening/ permanent damage Which Requires intensive treatment	Directly/indirectly contributes to the death of the patient

## CLASSIFICATION- Depending on type of reaction

### Type A- Augmented

- Exacerbation of pharmacological effect
- Predicted from the pharmacology of the drug
- Dose dependent
- Alleviated by dose reduction
- Detected in clinical trials
- High incidence, less severe
- High morbidity, low mortality

Anticoagulants → bleeding  
Beta blockers → bradycardia

### Type B- Bizarre

- Hyper sensitivity reaction
- Cannot be predicted
- Not Dose dependent
- Cannot be detected in clinical trials
- Cannot be alleviated by dose reduction
- Low incidence, more severe
- Low morbidity, high mortality

Penicillin → Anaphylaxis  
Anticonvulsant → Hypersensitivity

### Type C- Chronic/continuous

- Prolonged exposure to a drug
- Dose & time related
- Exact mechanism unknown
- Irreversible, unexpected & unpredictable

Biphosphonates → Osteonecrosis

### Type D- Delayed

- Delayed long after drug exposure
- Diagnosis is difficult
- Uncommon reactions
- Due to drug accumulation

Antipsychotics → Tardive dyskinesia  
Chemotherapy → Secondary tumors

### Type E-End of Use

- Withdrawal syndrome (abrupt)
- Uncommon
- Can be managed by reintroducing & withdrawing it slowly

Phenytoin → Seizure  
Steroid → Adrenocortical insufficiency

### Type F-Failure of therapy

- unexpected
- Reduction in drug's efficacy
- By drug interaction

Oral contraceptive + other drugs  
→ pregnancy

## PREDISPOSING FACTORS

Race & Genetic factors

Genetically predisposed individual can have ADR

Polypharmacy

Multiple drug therapy can cause ADR

Diseases

Altered physiological function can cause ADR

Women are more prone to ADR due to hormonal impact

Gender

Age

Drug characteristics

Certain drugs have narrow therapeutic range

Paediatrics & geriatrics are more prone to ADR

SOME OTHER CATEGORIES OF ADR:

**Side effects:**

Unwanted, but unavoidable effects of the drug at therapeutic dose

**Toxic effects:**

Excessive pharmacologic action due to over dosage or prolonged dose

**Secondary effects:**

Indirect consequences of primary action of drug

**Intolerance:**

Appearance of characteristic toxic effects in an individual at therapeutic doses

**Idiosyncrasy:**

Abnormal reactivity to a chemical (due to unique feature of the individual)

**Drug allergy:**

immunologically mediated reaction towards the drug given.

SOME OTHER CATEGORIES OF ADR:

**Photosensitivity:**

Cutaneous reaction resulting  
from drug induced  
sensitisation to UV radiation

**Drug dependence:**

Use of drugs for personal  
satisfaction rather than  
basic need

**Drug withdrawal reactions:**

Sudden interruption of  
therapy cause certain  
adverse reactions

**Teratogenicity:**

Capacity of the drug to cause  
foetal abnormalities when  
administered to the pregnant  
mother

**Mutagenicity &  
Carcinogenicity:**

Ability of drugs to alter genes  
or produce cancer

**Iatrogenic:**

Functional disturbances  
caused by drugs, which  
persist even after  
withdrawal of drugs



## PHARMACOVIGILANCE

*Pharmacovigilance can be defined as the 'science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug related problems.'*

- The **Uppsala Monitoring Centre** (Sweden) is the international collaborating centre.
- In India, the Central Drugs Standard Control Organization (CDSCO) is coordinating the pharmacovigilance programme,
- Under CDSCO, numerous peripheral, regional and zonal monitoring centres have been set up along with a National Pharmacovigilance advisory committee.
- The PV centres collect, communicate and disseminate ADR data by linking with hospitals as well as practitioners
- provide expertise for assessing causality and severity of ADRs by using standard algorithms and rating scales.

ADR monitoring by PMS, voluntary reporting,  
prescription event monitoring etc.


Dissemination  
of ADR  
through drug  
alerts, medical  
alerts etc.

**Activities  
involved  
in PV**

Changes in labelling  
of medicines  
indicating  
restriction in use  
statuary warning  
withdrawal of drugs

## MONITORING OF ADR

NEED:



How can we monitor?

- Patient interview
- Reviewing prescriptions
- Abrupt cessation of medicines
- Obtaining previous medical history

## MONITORING OF ADR



## METHODS

### 1. PRE MARKETING STUDIES

- During study in animal models, safety is tested in animal models
- Specific animal studies for carcinogenicity, mutagenicity, teratogenesis, immunotoxicity etc.
- Conducted during 3 phases before drug is being marketed.
- Clinical trials identifies ADRs of frequency 0.5-1.0%

#### Pre- Marketing Studies

Phase 1



Phase 2



Phase 3

## 2. POST MARKETING SURVEILLANCE/ STUDIES

### SPONTANEOUS ADR REPORTING


- ✓ Health professionals voluntarily submit the ADR
- ✓ Inorder to mitigate the impact of ADR on society

### CASE CONTROL STUDIES

- ✓ Individuals affected by ADR is being studied.
- ✓ Both cases & control are investigated for their exposure to possible causative agent

### COHORT STUDIES

- ✓ Patient exposed to a particular drug is followed up for ADR .
- ✓ ADR frequencies are compared to unexposed population



### 3. CAUSALITY ASSESSMENT

- ✓ Method by which extent of relationship b/w a drug and a suspected reaction is established.
- ✓ Once ADR is suspected, assessment starts with collection of all data
  - ✓ Patient demographics
  - ✓ Medication including OTC
  - ✓ Time of onset of action
  - ✓ Duration of onset of action
  - ✓ Treatment of reaction
  - ✓ Outcome of the treatment
  - ✓ Valid reports
- ✓ Assessment is made using different approaches
  - ✓ Opinion of individual experts
  - ✓ Opinion of panel of experts
  - ✓ Formal algorithms like WHO probability scale and Naranjo's algorithm.

Causality is assessed on the basis of:

Temporal relationship

- How the time-sequence of the event is related to drug administration.

Previous knowledge

- Whether the drug is known to produce the event in earlier recipients with a certain degree of consistency.

De-challenge:

- Whether the event subsided on stopping the drug.

Rechallenge:

- Whether the event reappeared when the drug was administered again after a gap during which the event had subsided.
- Many times rechallenge is unethical/dangerous, and is not done.



#### 4. COMMUNICATING ADRs

Knowledge about safe and rational use of drug should be provided

- ✓ During basic training of healthcare professionals
- ✓ Through continuous education programmes to health care professionals
- ✓ By specifically designed drug information centres
- ✓ Through packaged inserts as well as patient counselling

## **5. POSTAL SURVEY METHOD**

- Consists of specific drug related questionnaire
- Primarily for ADR monitoring of new drugs
- Asks for details of the drugs, usage, dose, brand, number of patients given treatment
- Common ADRs seen with drug are mentioned at the end of the questionnaire
- Questionnaire, along with a prepaid envelope is sent to the practitioners who are likely to use the drug.

# REPORTING OF ADR

## WHO CAN REPORT?

- Doctors
- Clinicians
- Pharmacists
- Consumers
- Nurses

## WHERE TO REPORT?

- Local / Peripheral centre
- Regional PV centre
- National PV centre
- WHO Collaborating Centres
- Manufacturers

## WHAT REACTIONS SHOULD BE REPORTED?

- Serious & life threatening reactions
- Fatal reactions
- Permanent harm/ disabilities
- Increased healthcare costs
- Any reactions to newer drugs
- Newer reactions to any drugs
- Rare & uncommon reactions

# REPORTING OF ADR

## INFORMATION TO BE INCLUDED

- Patient demographics
- Description of ADR
- Suspected drugs
- Dose, ROA of suspected drug
- Onset of ADR
- Description of ADR
- ADR Management details
- Concomitant diseases
- Current drug therapy details, along with OTC drugs
- Details of the reporter

## HOW TO REPORT?

- ✓ Reporting form/ phone call/ vigiflow/ tollfree number/ e-mail/mobile application.
- ✓ Should be on a standard form
- ✓ Use separate form for each patient
- ✓ fill the complete information
- ✓ The completed form must be returned to the nearest ADR Monitoring Centre / National Coordinating Centre
- ✓ Any follow-up information of an already reported ADR can either be filled in a new form or communicated via phone / e-mail



## TYPES OF ADR REPORTING FORMS

- **Suspected ADR Reporting Form**  
(For voluntary reporting BY Healthcare professionals)
- **ADR Reporting form for consumers**  
(For consumers)
- **Transfusion Reaction Reporting Form**  
(Haemovigilance Program of India)
- **Medical Device Adverse Event Reporting Form**  
(Materiovigilance program of India)

Form No. 10

**SUSPECTED ADVERSE DRUG REACTION REPORTING FORM**  
For Voluntary Reporting of ADRs by Healthcare Professionals  
**INDIAN PHARMACOPOEIA COMMISSION** (National Coordination Centre, Pharmacovigilance Programme of India)  
 Ministry of Health & Family Welfare, Government of India, Sector 25, 1st Floor, Okhla Industrial Estate, New Delhi-110025  
 PAFI Helpline (Toll Free) - 1800-180-3030 (Toll Free) 011-2610-3030

Form No. / 2019 No. / 2019 No. / 2019 No.		Form No. / 2019 No. / 2019 No. / 2019 No.																																																																			
<b>A. REPORTING ORGANIZATION</b> 1. Name of Organization 2. Name of Health Care Worker 3. Designation 4. Address (if any)		<b>B. PATIENT INFORMATION</b> 1. Name of Patient 2. Age 3. Sex 4. Date of Birth (dd-mm-yy) 5. Date of Admission (dd-mm-yy) 6. Date of Discharge (dd-mm-yy)																																																																			
<b>C. SUSPECTED ADVERSE REACTION</b> 1. Name of Suspected Adverse Reaction 2. Onset of Suspected Adverse Reaction (dd-mm-yy) 3. Duration of Suspected Adverse Reaction (dd-mm-yy) 4. Description of Suspected Adverse Reaction with Signs &/or Symptoms		<b>D. SUSPECTED DRUGS</b> 1. Name of Suspected Drug 2. Strength (if any) 3. Route of Administration 4. Date of Administration (dd-mm-yy) 5. Indication for Administration (if any)																																																																			
<b>E. MEDICATIONS CONCOMITANT</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Sr. No.</th> <th>Name of Drug (Brand Name)</th> <th>Strength (if any)</th> <th>Route of Administration</th> <th>Date of Administration</th> <th>Indication</th> </tr> </thead> <tbody> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> </tbody> </table>		Sr. No.	Name of Drug (Brand Name)	Strength (if any)	Route of Administration	Date of Administration	Indication																																																													<b>F. OUTCOME</b> 1. Date of Follow-up (dd-mm-yy) 2. Outcome of the Reaction (if any) 3. Date of Death (dd-mm-yy) (if applicable) 4. Date of Discharge (dd-mm-yy) (if applicable) 5. Date of Recovery (dd-mm-yy) (if applicable) 6. Date of Hospitalization (dd-mm-yy) (if applicable) 7. Date of Death (dd-mm-yy) (if applicable) 8. Date of Discharge (dd-mm-yy) (if applicable) 9. Date of Recovery (dd-mm-yy) (if applicable) 10. Date of Hospitalization (dd-mm-yy) (if applicable)	
Sr. No.	Name of Drug (Brand Name)	Strength (if any)	Route of Administration	Date of Administration	Indication																																																																
<b>G. ADDITIONAL INFORMATION</b> 1. Name of Reporting Organization 2. Address of Reporting Organization 3. Telephone No. 4. Fax No. 5. E-mail Address 6. Website Address 7. Name of Reporting Officer 8. Designation of Reporting Officer 9. Date of Reporting (dd-mm-yy)		<b>H. REPORTING OFFICER</b> 1. Name of Reporting Officer 2. Designation of Reporting Officer 3. Address of Reporting Officer 4. Telephone No. 5. Fax No. 6. E-mail Address 7. Website Address 8. Date of Reporting (dd-mm-yy)																																																																			

Signature and Stamp of Reporting Organization

Signature and Stamp of Reporting Officer

Comments: This form is to be filled in and submitted to the National Coordination Centre, Pharmacovigilance Programme of India.

## FATE OF ADR REPORTS



A white, 3D-rendered speech bubble is mounted on a thin wooden stick. The bubble is centered on a light blue background. Inside the bubble, the words "THANKYOU" are written in a bold, sans-serif font. "THANK" is in a teal color, and "YOU" is in a reddish-orange color. The bubble has a slight shadow on the surface below it, giving it a three-dimensional appearance.

THANKYOU